naloxone hydrochloride
AssetAlso called naloxone, NSC-70413, EN-15304, NSC-757109
Blocks opioid receptors, reversing opioid-mediated effects.
- Stage
- Approved
- Modality
- Small molecule
- Target
- OPRM1
- 14
- Indications
- 125
- Trials
- 4
- Developers
Approved by the FDA on Apr 13, 1971 (NDA016636). 2 approvals stand. FDA
Indications
14Opioid overdose
Approved, SEC filing
Overdose
Approved, FDA
Opioid dependence
Phase 3, Completed, NCT02038790, clinicaltrials.gov, Nov 4, 2026
11 more
In the full profile
- Target and mechanism4
- Owner and partners5
- Trials125
- Evidence for its targets4
- Competitors12
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.